Curated News
By: NewsRamp Editorial Staff
October 09, 2026
CCHR Urges FDA to Reject Psychedelic Drugs for Mental Health
TLDR
- CCHR urges FDA to reject psychedelic approvals, arguing these drugs add psychosis and violence risks without cures.
- CCHR's FDA comments outline contraindications like pregnancy and epilepsy, plus safeguards on consent, monitoring, and reporting requirements.
- CCHR seeks to protect vulnerable patients from psychedelic harms by demanding strict FDA limits on consent and administration.
- CCHR notes that psychedelic trials often fail blinding, with nearly all participants guessing whether they received the drug.
Impact - Why it Matters
This news matters because the FDA is actively considering approving psychedelic drugs for mental health conditions, which could lead to a new class of widely prescribed psychotropics with serious risks. CCHR's opposition highlights concerns about safety, informed consent, and the potential for adverse effects like psychosis and violence. If approved without strict safeguards, these drugs could expose patients to significant harm, especially those with preexisting conditions. The debate also underscores broader questions about the efficacy and ethics of psychiatric treatments, making it crucial for patients, healthcare providers, and regulators to critically evaluate the evidence before embracing psychedelics as a solution to the mental health crisis.
Summary
The Citizens Commission on Human Rights International (CCHR) has formally opposed the FDA's potential approval of psychedelic drugs for mental disorders, submitting comments in response to the agency's request for input on "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs." In its CCHR's submission, the watchdog argues that approval would introduce another class of psychotropic drugs with high risks of aggression, psychosis, and violence. Jan Eastgate, President of CCHR International, criticized the move, stating, "Existing psychiatric drugs already carry serious risks and have not cured any mental disability. A new class of perception-altering drugs is now offered for problems that prior psychiatric drugs have caused."
CCHR highlights that classic psychedelics such as LSD, psilocybin, DMT, and mescaline are serotonergic agents that can cause life-threatening serotonin syndrome when combined with SSRIs or other substances. The group notes contraindications for pregnancy, epilepsy, and severe cardiovascular disease, and points out that blinding in clinical trials often fails because participants can easily identify whether they received the drug. The FDA has issued Commissioner's National Priority Vouchers to three psychedelic programs under criteria including "innovative cures," but CCHR insists these drugs treat symptoms, not cure mental illness, as acknowledged by the American Psychiatric Association.
If any application proceeds, CCHR demands strict limits: no use under 18, during pregnancy, or in individuals with psychosis, suicidal intent, or violence history; a boxed warning and Medication Guide; two trained staff present; no take-home supply; and mandatory reporting of adverse events. CCHR International, founded in 1969 by the Church of Scientology and Professor Thomas Szasz, remains a vocal mental health industry watchdog, advocating for public protection against psychiatric drug harms.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, CCHR Urges FDA to Reject Psychedelic Drugs for Mental Health
